The US FDA has approved SIMLANDI – a biosimilar to (and less costly than) Humira for the treatment of adult rheumatoid arthritis and many other autoimmune diseases including IBD. SIMLANDI is a product of the partnership between Israel’s Teva and the multinational Alvotech.

https://www.tevapharm.com/news-and-media/latest-news/alvotech-and-teva-announce-u.s.-approval-of-simlandi-adalimumab-ryvk-injection-the-first-interchangea/